Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysis

Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysis

Schizophrenia presents a substantial clinical and economic burden to the health-care system. In QUAlity of LIfe with AbiliFY Maintena (QUALIFY), a randomized head-to-head study of aripiprazole once-monthly 400 mg (AOM 400) compared with paliperidone palmitate (PP; 78–234 mg/mo), AOM 400 demonstrated...

Full description

Bibliographic Details
Main Authors: Christophe Sapin, Ann Hartry, Siddhesh A Kamat, Maud Beillat, Ross A Baker, Anna Eramo
Format: Article
Language:English
Published: BioExcel Publishing Ltd 2016-09-01
Series:Drugs in Context
Subjects:
aripiprazole once-monthly
paliperidone palmitate
schizophrenia
cost-effectiveness
long-acting injectable agents
second-generation antipsychotic
health economics
patient functioning
Online Access:http://www.drugsincontext.com/pharmacoeconomic-comparison-of-aripiprazole-once-monthly-and-paliperidone-palmitate-from-a-head-to-head-clinical-trial-in-schizophrenia-a-us-analysis/

Internet

http://www.drugsincontext.com/pharmacoeconomic-comparison-of-aripiprazole-once-monthly-and-paliperidone-palmitate-from-a-head-to-head-clinical-trial-in-schizophrenia-a-us-analysis/

Similar Items